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Abstract
Methadone substitution improves maternal and neonatal
outcomes. However methadone induced neonatal
abstinence syndrome (NAS) is common. Buprenorphine-
exposed neonates may be at a lower risk of NAS. Currently
in the Republic of Ireland, buprenorphine does not have a
special licence for use in pregnancy. We describe here the
history and neonatal outcomes of the first Irish woman
maintained on buprenorphine during two pregnancies.
Supervised urinanalysis on this mother between and
throughout both pregnancies did not reveal any illicit drug
use. She delivered two post-term babies of normal birth
weight and length. The second infant required treatment for
NAS for 21 days with morphine sulphate. Although the use
of buprenorphine in pregnancy does not remove the
possibility of NAS, neonatal outcomes of buprenorphine-
maintained women compares favourably to methadone. As
the use of buprenorphine becomes more established in
Ireland, the management of buprenorphine-exposed
neonates will become more common. 
Key words: Neonatal abstinence syndrome; Opiate
dependency; Buprenorphine.
Introduction
The incidence of heroin use in Ireland escalated through-
out the 1990s before tailing off at the end of the decade,1
only to increase again in recent years.2 However, reflecting
the chronic nature of opiate dependency, prevalence rates
have steadily increased. Recent estimates of opiate preva-
lence in Ireland are based on a three-source capture-
recapture study of opiate use in 2000-2001.3
This research showed that in the 15-64 year age group,
5.6/1000 of the population used opiates; local prevalence in
the Dublin area was amongst the highest in Europe at
15.9/1000. In the 15-24 year age group, prevalence esti-
mates were even higher at 32/1000 males and 17/1000
females. 
Increasingly more women are entering methadone substi-
tution treatment, the majority of childbearing age.
Internationally and in Ireland, methadone, a pure opiate
agonist, is the main substitution medication used in the treat-
ment of opiate dependency due to its proven ability to
stabilise the opiate-dependent person’s drug use and
lifestyle.4 Methadone facilitates engaging and retaining an
opiate-dependent individual in treatment so that at the very
least, they can be offered medical, psychological and social
support (‘harm reduction’). For methadone-maintained moth-
ers, treatment facilitates access to antenatal and obstetric
care, which can be co-ordinated by a drug liaison midwife. 
In 1999, a drug liaison midwife service was set up with one
midwife attached to each of the three Dublin Maternity Hospi-
tals. In the Republic of Ireland during 2005, there were 8,962
people prescribed methadone,5 of whom 2,746 were female
(30.6%), with a mean age of 29 years (SD +/- 6.4 yrs). And
during that year, there were 193 infants born in the three
Dublin maternity hospitals to women maintained on
methadone.6
Research has consistently demonstrated that maternal and
neonatal outcomes are better in methadone-maintained
mothers than for those mothers using opiates and not in
treatment.7-10 However, a neonatal abstinence syndrome
(NAS) occurs in 48-94% of infants exposed to methadone
in-utero.11
The signs of NAS include: high-pitched cry, rapid breath-
ing, hungry but ineffective sucking, excessive wakefulness,
tremor, vomiting and diarrhoea, hypertonicity, sweating, and
rarely, seizures. In the interest of objectivity, Loretta Finnegan
and colleagues developed the ‘Finnegan chart’ which allows
the assessment and monitoring of NAS.12 Numerical values
are allocated on the basis of the presence and severity of 20
signs commonly found in neonatal withdrawal (CNS, meta-
bolic, vasomotor, respiratory, and gastro intestinal
disturbances). The numbers are added together to give a
total score (maximum 46). 
The aims of managing an infant who is at risk of NAS are
to maintain a normal temperature, to ensure adequate sleep
between feeds, to reduce hyperactivity and excessive crying,
to reduce motor instability, and ensure adequate weight gain.
The hospital where these infants were delivered uses the
‘Liverpool approach’17 (an obstetric liaison service compris-
ing of a multidisciplinary team from the addiction and
midwifery services), and monitors for NAS with a modified
version of the Finnegan Scale. 
The decision to initiate treatment of opiate withdrawal with
morphine sulphate is made if any one score is greater than
12, or the infant scores eight or more on three successive
occasions. 
The dose and schedule of morphine sulphate substitution
is adjusted so as to maintain the daily Finnegan scores under
eight, and then gradually reduced as the infant shows
evidence of prospering.
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While research from our own service indicated that higher
maternal methadone doses are associated with increased
likelihood of NAS,13 debate on this issue exists in the litera-
ture.14,15 When NAS occurs, how long it lasts and how severe
it becomes depends on many factors including other drugs
used, the amounts used, when these were taken in relation
to delivery, and the condition of the infant after birth.16 As a
result of NAS, infants of methadone-maintained mothers may
require prolonged hospitalisation,17,18 which in addition to
disrupting family bonding, increases the costs to service
providers.
Since the mid 1990s, buprenorphine (Subutex), a mixed
agonist-antagonist has become increasingly available in
Europe as an alternative to methadone. In 2002, legislative
changes in Ireland allowed buprenorphine to be prescribed
to non-pregnant people requiring substitution treatment.
Whereas methadone is a full agonist at the mu-opiate recep-
tor, and as formulated for use in Ireland, cannot be injected,
buprenorphine is a partial agonist at the mu-receptor, an
antagonist at the K-opiate receptor, and can be injected. 
Research on adults suggests that buprenorphine may be
easier to withdraw from than methadone.19 In addition
buprenorphine may have advantages over methadone in
pregnancy, as the incidence and severity of NAS appears to
be less20-24 resulting in less distress to the infant and mother,
and shorter hospital admissions. This may reflect the differ-
ent receptor profile of buprenorphine.25
More definitive evidence may come from the ‘Mother
Opioid Treatment: Human Experimental Research’ project
(MOTHER), the first large, multicentre, randomised, double-
blind study to compare methadone and buprenorphine for the
treatment of pregnant opiate-dependent pregnant women
and the effect on the NAS.26 Preliminary data suggests that
buprenorphine results in improved birth outcomes and less
neonatal abstinence syndrome relative to methadone.27,28
In addition, whereas breast-fed infants of mothers who
continue on methadone have been found to have less severe
NAS and require as a result to be weaned off breast-feeds,29
buprenorphine levels in breast milk have little or no effect on
the NAS.30 However as buprenorphine can be injected some
argue that this undermines one of the main benefits of
methadone, which is reducing injecting behaviour and the
spread of blood-borne diseases. 
To counter this abuse potential, buprenorphine has been
combined with naloxone (Suboxone) in a 4:1 ratio. Naloxone,
a pure opiate competitive antagonist with good parenteral but
poor oral/sublingual bioavailability, will precipitate opiate with-
drawal in opiate-dependent individuals when injected – this
aversive effect lessens the risk of diversion and intravenous
misuse. As a result, this combined buprenorphine prepara-
tion is likely to be the main alternative to methadone in
Ireland. 
Whilst teratology studies on animals reveal no embryo-
genic/teratotogenic effects associated with methadone or
buprenorphine, there are concerns of reproductive toxicity
related to naloxone.31 Therefore women maintained on
buprenorphine/naloxone who become pregnant should be
switched over to buprenorphine when pregnancy is
confirmed.31,32
As the use of buprenorphine preparations to treat opiate-
dependence becomes more established in Ireland,
conception and pregnancy while on buprenorphine treatment
and the subsequent management of such pregnancies will
also become more frequent.  
Case report
Ms A grew up in a family with no known history of alco-
hol/substance misuse or psychiatric illness. She left school
when she was 16 years old after passing the Junior Certifi-
cate and began working. Through associating with an older
age group, she was introduced to illegal drugs. She first used
heroin when she was 16 years old (‘skin-popping’) and
quickly progressed to daily intravenous use of heroin (and
cocaine). Soon she had moved out of the family home to
become homeless. With the future father of her children, she
spent three periods living homeless in a city in England.
During the first visit in 2000, she developed a femoral vein
thrombosis, and commenced methadone maintenance treat-
ment for the first time. On returning to Ireland, she completed
a three-month outpatient detoxification, but relapsed and
went back to England with her boyfriend. After several
months of chaotic drug use, she self-detoxed and returned to
Ireland, where she remained abstinent for about 18 months.
In 2004, she and her boyfriend returned to England for the
last time. Again they lived a homeless drug-dependent
lifestyle until Ms A was identified and engaged into treatment.
During the assessment process, she discovered she was
pregnant (and positive for hepatitis C). 
Instead of methadone, she chose buprenorphine substitu-
tion treatment, and stabilised on 12mg. Emergency
accommodation was arranged for her but not her partner, as
he did not enter treatment, and subsequently they lost
contact. Late in her pregnancy, Ms A decided to return to live
with her parents in Dublin. In January 2005 as arranged, she
presented for treatment to the Drug Treatment Centre Board.
She was 21 years old and 36 weeks pregnant.
A decision was made to continue buprenorphine rather
than switch to methadone due to her imminent delivery. Ms A
was assigned a drug liaison midwife and linked in with the
obstetric services. 
Her urines were closely monitored and remained negative
for all drugs of abuse. One month later she gave birth to a
healthy baby. A few weeks later, on release from prison, her
partner returned to live with her in Ireland.  
Ms A continued buprenorphine maintenance treatment
following the birth of her baby and became pregnant again
after a few months. Early in her second pregnancy, Ms A
complained of symptoms that she associated with opiate
withdrawal. These settled on increasing the dose of
buprenorphine incrementally to 16mg. 
Late in this second pregnancy, her partner returned to
England and unfortunately died from a brain haemorrhage.
Ms A moved back to live with her parents, did not relapse and
continued to give clean urines. She gave birth to her second
child in early 2006. During both pregnancies, she abstained
from alcohol, and tried to smoke less than 10 cigarettes per
day.
Neonatal outcomes 
Table 1 compares the birth parameters of these two
infants. Both of this woman’s pregnancies were without
complication. Both infants were delivered post-term, and
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were healthy at delivery, with normal birth weights for gesta-
tional age relative to the mother’s height (157cm) and weight.
Neurodevelopmental examinations at six months were also
normal. Neither infant was breastfed.
Baby one
This infant girl was a spontaneous non-instrumental vertex-
vaginal delivery, during which the mother did not require
analgesia. She developed mild symptoms of neonatal absti-
nence in the first day, with a maximum Finnegan score of nine
on two occasions. These scores reflected mild irritability
overnight due to mild tremors, sneezing, loose stools and
secondary excoriation of the buttock area. Treatment for NAS
was not required. By day five she was gaining weight, and
was ready for discharge with her mother. The baby’s weight
on discharge was 2.84kg, and two weeks later was 3.25kg.
At this check-up, the mother reported very occasional sweat-
ing episodes but no jitteriness. 
Baby two
In contrast, baby two was induced at two weeks post-term.
This delivery was more distressing for the mother, as on this
occasion she required pethidine analgesia. The third stage of
delivery took 35 minutes. The placental cord was around this
infant’s neck, but the baby was not distressed, cried at deliv-
ery, and Apgar scores were normal. Mild but significant
symptoms of NAS developed within the first 24 hours
(Finnegan Scores 6, 5). 
On day two, this baby boy was admitted to the neonatal
intensive care unit in order to facilitate the mother attending
her partner’s cremation. The mother was subsequently
discharged on day five. 
Symptoms of NAS continued to increase during the
second day (8, 4, 11) peaking at 15 by 42 hours, at which
time substitution treatment with morphine sulphate was initi-
ated (0.2mg every three hours). The dose was gradually
reduced, and the interval between doses slowly extended, so
that by day nine the infant was stable on 0.1mg every six
hours and had reached a lowest weight of 3.24kg. With a
gain of 10g by day 10, the interval was extended to eight-
hourly, however the infant became distressed, but settled
again on six-hourly doses. 
During the next few days this regime was continued whilst
the baby continued to put on weight. Detoxification was
recommenced at day 16 and successfully completed on day
23. The total duration of treatment with morphine sulphate
was 21 days. This period of detoxification was also compli-
cated by a pseudomonas eye infection treated with topical
gentamycin from day six, and augmented with fucidic acid
from day 25. The infant was ready for discharge on day 26
(weight 3.84kg), but this was deferred until day 30 for non-
medical reasons (weight 4.10 kg).
Discussion
This unique case history describes the neonatal outcomes
of two infants delivered to a mother who successfully
stabilised on buprenorphine substitution therapy. Unlike baby
one, baby two had a prolonged hospital stay as a result of
significant NAS. The duration of treatment was similar to the
mean treatment period shown in a previous Irish study by
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Characteristic Baby one Baby two
Primagravida Para 1+0
Mother’s weight at booking Not known 52kg
Exposed to buprenorphine After conception At conception (12mg)
Buprenorphine dose at delivery 12mg once daily 16mg once daily
Antenatal ultrasound Normal Normal
Gestational age 41 + 1 42
Delivered by Spontaneous vaginal delivery Induced vaginal delivery
Sex of infant Female Male
Weight of infant 3.24kg 3.6kg
Lowest weight 2.89kg 3.24kg
Length of infant (crown-heel) 49cm 51cm
Head circumference (32-37 cm) 35cm 35cm
Apgar score 1, 5 minutes 9, 10 9, 10
Maximum NAS score 9 (x 2) 16
Length of stay in Neonatal ICU Not admitted 29 days
Length of substitution treatment Not initiated 21 days – day 2 to day 23
Total length of hospital stay 5 days 30 days – ready for d/c D26
Six week check-up Normal – weight 4.57 kg Normal – weight 4.71 kg
Head circum 37cm Head circum 38 cm
Table 1: Birth parameter comparison for baby one and baby two
Coghlan and colleagues in the same maternity hospital.18 This
study showed that the mean duration of treatment for an
infant with NAS was 21.8 days (range 1-62 days); however,
only six of the 43 infants reviewed were exposed to
methadone alone, with a mean duration of treatment of 17
days.
The widely diverse degree of NAS between these two
infants and the documented history of illicit drug abstinence
by their mother, make it easier to appreciate that even in such
ideal circumstances, it is not possible to predict the likelihood
and degree of NAS a newborn might experience. Other
factors must contribute to opiate related NAS, an area
warranting further research. 
Possible other factors contributing to the severity of NAS
in baby two’s case might include:
• Exposure to buprenorphine from conception
• As with methadone, the possibility of a dose effect. Early
pregnancy symptoms can mimic withdrawal,17 and this may
explain the mother’s need for an increased dose in the first
trimester 
• Six days older at delivery – pre-term babies appear to be
less effected by NAS, and reasons postulated include a
shorter duration of exposure to drugs, and a less mature
nervous system33
• Labour was induced
• Pethidine was administered which may have contributed to
opiate withdrawal 
• Psychosocial stress factors related to the sudden death of
the mothers partner. Perhaps she smoked more as a result
of this unexpected event. Research has shown that nicotine
can contribute to NAS in methadone-exposed neonates34
• Did urine drug toxicology accurately reflect abstinence from
illicit drugs? New clients to the addiction services initially
provide twice weekly, and later weekly, random urine
samples, which are tested for the presence of opiates,
methadone, benzodiazepines, cocaine, amphetamine,
cannabis and alcohol. Short acting non-benzodiazepine
sedatives are not routinely screened for. However the dura-
tion of negative toxicology suggests that she was truly
abstinent.
Conclusion
Buprenorphine treatment for pregnant opiate-dependent
women compares favourably to methadone. As this case
shows, widely diverse neonatal outcomes can still be
expected with buprenorphine substitution in pregnancy even
when only exposed to buprenorphine in-utero. As the use of
buprenorphine preparations for substitution and maintenance
becomes more established in Ireland, the need to manage
buprenorphine-exposed neonates will become more
common.
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